Incretin-Based Therapy and Respiratory Function in Obesity: New Trial to Deploy Machine Learning for Predicting Pulmonary Outcomes

References

1. 1.Biruni University. (2025). Prediction of changes in pulmonary function, respiratory muscle performance, and ventilatory responses following incretin-based therapy in individuals with obesity using machine learning (NCT07663591). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07663591
2. 2.Salome, C. M., King, G. G., & Berend, N. (2010). Physiology of obesity and effects on lung function. Journal of Applied Physiology, 108(1), 206–211. https://doi.org/10.1152/japplphysiol.00694.2009
3. 3.Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. 4.Evans, J. A., & Whitelaw, W. A. (2009). The assessment of maximal respiratory mouth pressures in adults. Respiratory Care, 54(10), 1348–1359. https://doi.org/10.4187/002013209790514386
5. 5.Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J. (2023). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205. https://doi.org/10.1056/NEJMoa2404881
6. 6.Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183